Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines

被引:105
作者
Heikkilä, P
Teronen, O
Moilanen, M
Konttinen, YT
Hanemaaijer, R
Laitinen, M
Maisi, P
van der Pluijm, G
Bartlett, JD
Salo, T
Sorsa, T
机构
[1] Univ Helsinki, Cent Hosp, Dept Med Biomedicum & Oral Med, Diagnost Lab, FIN-00014 Helsinki, Finland
[2] Invalid Fdn, ORTON Res Inst, Helsinki, Finland
[3] TNO Prevent & Hlth, Leiden, Netherlands
[4] Univ Oulu, Dept Diagnost & Oral med, Oulu, Finland
[5] Oulu Univ, Cent Hosp, SF-90220 Oulu, Finland
[6] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland
[7] Tampere Univ, Cent Hosp, Dept Surg, SF-33520 Tampere, Finland
[8] Tampere Univ, Cent Hosp, Dept Oral & Maxillofacial Surg, SF-33520 Tampere, Finland
[9] Univ Helsinki, Fac Med Vet, Dept Vet Clin Sci, Helsinki, Finland
[10] Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands
[11] Forsyth Inst, Harvard Forsyth Dept Oral Biol, Boston, MA 02115 USA
关键词
bisphosphonates; inhibition; invasion; matrix metalloproteinases; migration;
D O I
10.1097/00001813-200203000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Bisphosphonates (clodronate, alendronate, pamidronate and zoledronate) at therapeutically attainable non-cytotoxic concentrations Inhibited MMP-3, -12, -13 and -20 as well as MMP-1, -2, -8 and -9, but not urokinase-type plasminogen activator (uPA), a serine proteinase and a pro-MMP activator. Dose-dependent Inhibition was shown by three Independent MMP assays. The inhibition was reduced In the presence of an Increased concentration of Ca2+ when compared to physiologic Ca2+ concentration. Alendronate inhibited the In vitro Invasion (Matrigel) of human HT1080 fibrosarcoma and C8161 melanoma cells, and the random migration of these malignant and endothelial cell lines capable of expressing MMPs and uPA. The concentration of alendronate required to inhibit 50% of the activity (IC50 = 40-70 muM) of MMPs corresponded to the IC50 of down-regulation of In vitro invasion and migration. The ability of bisphosphonates to down-regulate the in vitro invasion and random migration was comparable or slightly better in relation to the selective gelatinase inhibitor CTTHWGFTLC peptide. Alendronate but not CTTHWGFTLC peptide promoted the adhesion of HT1080 fibrosarcoma and C8161 melanoma cell lines on fibronectin. Bisphosphonates are broad-spectrum MMP inhibitors and this Inhibition Involves cation chelation. Bisphosphonates further exert antimetastatic, anti-invasive and cell adhesion-promoting properties, which may prevent metastases not only into hard tissues but also to soft tissues. [(C) 2002 Lippincott Williams Wilkins.].
引用
收藏
页码:245 / 254
页数:10
相关论文
共 43 条
[2]
A NOVEL METALLOPROTEINASE GENE SPECIFICALLY EXPRESSED IN STROMAL CELLS OF BREAST CARCINOMAS [J].
BASSET, P ;
BELLOCQ, JP ;
WOLF, C ;
STOLL, I ;
HUTIN, P ;
LIMACHER, JM ;
PODHAJCER, OL ;
CHENARD, MP ;
RIO, MC ;
CHAMBON, P .
NATURE, 1990, 348 (6303) :699-704
[3]
Boissier S, 2000, CANCER RES, V60, P2949
[4]
Boissier S, 1997, CANCER RES, V57, P3890
[5]
Changing views of the role of matrix metalloproteinases in metastasis [J].
Chambers, AF ;
Matrisian, LM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (17) :1260-1270
[6]
Bisphosphonates in the treatment of bone diseases [J].
Delmas, PD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) :1836-1837
[7]
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment [J].
Derenne, S ;
Amiot, M ;
Barillé, S ;
Collette, M ;
Robillard, N ;
Berthaud, P ;
Harousseau, JL ;
Bataille, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2048-2056
[8]
Reduction in new metastases in breast cancer with adjuvant clodronate treatment [J].
Diel, IJ ;
Solomayer, EF ;
Costa, SD ;
Gollan, C ;
Goerner, R ;
Wallwiener, D ;
Kaufmann, M ;
Bastert, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :357-363
[9]
Farina AR, 1998, CANCER RES, V58, P2957
[10]
BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE [J].
FLEISCH, H .
DRUGS, 1991, 42 (06) :919-944